MiMedx Group (MDXG) Solid Business Momentum; Time to Look at Clovis Oncology (CLVS)


Shares of MiMedx Group, Inc. (Nasdaq:MDXG) soared over 10% in the extended session Wednesday after the company said that it expects to deliver first quarter 2016 adjusted earnings per share in the range of $0.06 to $0.07, exceeding the Capital IQ Consensus Estimate of $0.05 earnings per share for the period. MiMedx also projects full year 2016 profit and revenue numbers above Wall Street analysts’ expectations

MDXG stock closed at $8.10, down $0.19 (or -2.29%), and 1,690,290 of its shares exchanged hands during the day

MiMedx Group, a regenerative medicine company, has 108.96M Shares Outstanding, Market Capitalization (intraday) of $882.59M and MDXG stock 52-week range is between $6.71 and $13.20 per share



Investment analysts at Janney Capital initiated coverage on Clovis Oncology, Inc. (Nasdaq:CLVS) shares with a Buy rating and a price target of $50.00, representing an upside potential of 53.7% versus its price at close on Wednesday of $32.53 per share

The company said that the review period for its investigational therapy rociletinib has been extended by three months to June 28, 2016 by the FDA

Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents, has 38.32M Shares Outstanding, Market Capitalization (intraday) of $1.25B and CLVS stock one-year range is from $24.50 to $116.75 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/